How to Accelerate the Future of Oncology with Keith Flaherty, President of the AACR

What happens when a world-class biologist decides that academic research isn't moving fast enough for patients? Dr. Keith Flaherty is a physician, scientist, and founder who obsesses over the "wiring of cells". As the Director of Clinical Research at the Mass General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School, he has authored over 300 peer-reviewed research publications. But he didn't stop at academia. He went on to co-found Loxo Oncology and Scorpion Therapeutics, driving billions in acquisitions and fundamentally changing precision cancer care. In this episode, Keith joins Dr. Jurgi Camblong to discuss his journey from early cell biology to becoming president of the AACR. They explore the evolution of melanoma treatments, the mechanics of targeted inhibitors, and the friction in the system that prevents us from learning from every patient. Because better outcomes don’t come from better science alone. They come from making the whole system work. #Oncology #PrecisionMedicine #AACR #DrugDevelopment #DecodedPodcast